MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock in private...
$103,368K
Proceeds from exercise of
stock options
$335K
Net cash provided by
financing activities
$103,703K
Net change in cash
and cash...
$35,894K
(155.61%↑ Y/Y)
Canceled cashflow
$67,809K
Proceeds from maturities
of marketable...
$25,602K
(-38.28%↓ Y/Y)
Stock-based compensation
expense
$1,481K
(-51.20%↓ Y/Y)
Accrued expenses and
other current...
$943K
(-0.11%↓ Y/Y)
Prepaid expenses and
other current assets
-$327K
(74.29%↑ Y/Y)
Other long-term
assets
-$304K
(-122.49%↓ Y/Y)
Accounts payable
$200K
(21.21%↑ Y/Y)
Operating lease
liabilities
$67K
(161.47%↑ Y/Y)
Depreciation and
amortization expense
$33K
(-13.16%↓ Y/Y)
Net cash used in
investing activities
-$57,263K
(-50.83%↓ Y/Y)
Net cash used in
operating activities
-$10,546K
(60.33%↑ Y/Y)
Canceled cashflow
$25,602K
Canceled cashflow
$3,355K
Purchases of marketable
securities
$82,605K
(4.08%↑ Y/Y)
Net loss
-$13,498K
(54.16%↑ Y/Y)
Purchases of property and
equipment
$260K
(237.66%↑ Y/Y)
Accretion of discounts on
marketable securities, net
$386K
(-68.87%↓ Y/Y)
Unrealized foreign
currency transaction...
$16K
(166.67%↑ Y/Y)
Non-cash operating lease
expense
-$1K
(-101.14%↓ Y/Y)
Back
Back
Cash Flow
Climb Bio, Inc. (CLYM)
Climb Bio, Inc. (CLYM)
source: myfinsight.com